Value proposition

To disrupt the endodontic device and consumable market by setting a new standard of care.

Odne AG (formerly Lumendo AG), has its roots in a groundbreaking collaboration between two renowned Swiss institutions: the Swiss Federal Institutes of Technology in Lausanne and Zürich (EPFL & ETH Zürich). Founded in 2018, Odne’s journey began by licensing cutting-edge technology assets from these esteemed institutes.

Odne is committed to pioneering the future of endodontics through advanced technology and innovative solutions. Endodontics, the field of dental medicine that deals with root canal treatments, has been marred by complexity and unpredictability. Odne is on a mission to change that.

Root canal treatments have long posed challenges for dentists, with traditionally low success rates ranging from 46% to 91%. With over 60 million annual treatments worldwide, these failures result in significant healthcare costs. Odne’s technology platform addresses these issues by offering treatment options for both dentists and their patients. Odne`s medical device portfolio, slated for launch in the US in 2024, tackle problems such as the debridement and obturation of complex root canal morphologies. Recently Odne Inc, USA was founded to build the organization to support the US launch.

Odne is backed by venture capital funds focusing on healthcare and dental. Recently Revere Partner (NY), an independent venture fund providing capital for cutting-edge innovations in oral and systemic health, and NV Capital (LIE), a family-owned venture capital boutique led the Series A1 financing. Alongside the lead investors other renowned funds such as Dental Innovation Alliance (DIA), Plug&Play, Hatcher, Züricher Kantonalbank, as well as various family offices and angel investors are supporting Odne's US market launch.